Search

Your search keyword '"COPPOLA, Nicola"' showing total 7 results
Start Over Author "COPPOLA, Nicola" Journal bmc infectious diseases
7 results on '"COPPOLA, Nicola"'

2. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Author

Colagrossi, Luna, Hermans, Lucas E., Salpini, Romina, Di Carlo, Domenico, Pas, Suzan D., Alvarez, Marta, Ben-Ari, Ziv, Boland, Greet, Bruzzone, Bianca, Coppola, Nicola, Seguin-Devaux, Carole, Dyda, Tomasz, Garcia, Federico, Kaiser, Rolf, Köse, Sukran, Krarup, Henrik, Lazarevic, Ivana, Lunar, Maja M., Maylin, Sarah, Micheli, Valeria, Mor, Orna, Paraschiv, Simona, Paraskevis, Dimitros, Poljak, Mario, Puchhammer-Stöckl, Elisabeth, Simon, François, Stanojevic, Maja, Stene-Johansen, Kathrine, Tihic, Nijaz, Trimoulet, Pascale, Verheyen, Jens, Vince, Adriana, Lepej, Snjezana Zidovec, Weis, Nina, Yalcinkaya, Tülay, Boucher, Charles A. B., Wensing, Annemarie M. J., Perno, Carlo F., Svicher, Valentina, and on behalf of the HEPVIR working group of the European Society for translational antiviral research (ESAR)

Published
2018
Full Text
View/download PDF

3. Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

Author

Coppola Nicola, Pisaturo Mariantonietta, Tonziello Gilda, Sagnelli Caterina, Sagnelli Evangelista, and Angelillo Italo F

Subjects
Antiviral therapy in HCV patients, Meta-analysis, Response to anti-HCV therapy, Tolerability of anti-HCV therapy, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Two formulations of Pegylated interferon (Peg-IFN) are on the market for treatment of chronic hepatitis C virus (HCV) infection. The purpose of this meta-analysis was to assess the efficacy of Peg-IFN α-2a versus Peg-IFN α-2b in combination with ribavirin in anti-human immunodeficiency virus (HIV)-negative patients with genotype 1 chronic HCV infection. Methods The following criteria were to be met for inclusion in the meta-analysis: (a) original data from randomized and non-randomized clinical trials; (b) study on the efficacy of conventional doses of Peg-IFN α-2a (180 μg/week) versus Peg-IFN α-2b (1.5 μg/kg of body weight/week), both in combination with ribavirin, in antiviral therapy-naïve HCV-genotype 1 subjects; (c) at least one of these primary outcomes: Rapid Virological Response (RVR); Early Complete Virological Response (EVR); End of Treatment Response (ETR); Sustained Virological Response (SVR); (d) odds ratio estimates of relative risk (RR) and associated 95% confidence intervals (CIs) or at least data enabling them to be computed; (e) English language; and (f) published as a full paper up to December 2011. Results Seven published studies met the inclusion criteria, allowing a meta-analysis on 3,026 patients. Peg-IFN α-2a and Peg-IFN α-2b showed similar rate of RVR (RR = 1.05; 95% CI = 0.87-1.27, p = 0.62) and SVR (RR = 1.08; 95% CI = 0.99-1.18, p = 0.098). Peg-IFN α-2a more frequently than Peg-IFN α-2b achieved EVR (RR = 1.11; 95% CI = 1.02-1.21, p = 0.013) and ETR (RR = 1.22; 95% CI = 1.14-1.31, p Conclusion The standard schedules of Peg-IFN α-2a and Peg-IFN α-2b, both in combination with ribavirin, can be used indifferently for patients with chronic HCV genotype 1 who are anti- to eliminate HIV-negative and antiviral treatment-naïve.

Published
2012
Full Text
View/download PDF

5. Efficacy of pegylated interferon 73945;-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis.

Author

Coppola, Nicola, Pisaturo, Mariantonietta, Tonziello, Gilda, Sagnelli, Caterina, Sagnelli, Evangelista, and Angelillo, Italo F.

Subjects
GENETIC research, HIV-positive persons, GENETIC polymorphisms, ANTIVIRAL agents, LIVER diseases
Abstract

Background: Two formulations of Pegylated interferon (Peg-IFN) are on the market for treatment of chronic hepatitis C virus (HCV) infection. The purpose of this meta-analysis was to assess the efficacy of Peg-IFN α-2a versus Peg-IFN α-2b in combination with ribavirin in anti-human immunodeficiency virus (HIV)-negative patients with genotype 1 chronic HCV infection. Methods: The following criteria were to be met for inclusion in the meta-analysis: (a) original data from randomized and non-randomized clinical trials; (b) study on the efficacy of conventional doses of Peg-IFN α-2a (180 µg/week) versus Peg-IFN α-2b (1.5 µg/kg of body weight/week), both in combination with ribavirin, in antiviral therapy-naïve HCV-genotype 1 subjects; (c) at least one of these primary outcomes: Rapid Virological Response (RVR); Early Complete Virological Response (EVR); End of Treatment Response (ETR); Sustained Virological Response (SVR); (d) odds ratio estimates of relative risk (RR) and associated 95% confidence intervals (CIs) or at least data enabling them to be computed; (e) English language; and (f) published as a full paper up to December 2011. Results: Seven published studies met the inclusion criteria, allowing a meta-analysis on 3,026 patients. Peg-IFN α-2a and Peg-IFN α-2b showed similar rate of RVR (RR = 1.05; 95% CI = 0.87-1.27, p = 0.62) and SVR (RR = 1.08; 95% CI = 0.99-1.18, p = 0.098). Peg-IFN α-2a more frequently than Peg-IFN α-2b achieved EVR (RR = 1.11; 95% CI = 1.02-1.21, p = 0.013) and ETR (RR = 1.22; 95% CI = 1.14-1.31, p < 0.0001). Conclusion: The standard schedules of Peg-IFN α-2a and Peg-IFN α-2b, both in combination with ribavirin, can be used indifferently for patients with chronic HCV genotype 1 who are anti- to eliminate HIV-negative and antiviral treatment-naïve. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

6. The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy

Author

Eliana Di Fiore, Albert Nienhaus, Stefania De Pascalis, Giuseppe Signoriello, Anna Rita Corvino, Evangelista Sagnelli, Nicola Coppola, Monica Lamberti, Coppola, Nicola, Corvino, Anna Rita, De Pascalis, Stefania, Signoriello, Giuseppe, Di Fiore, Eliana, Nienhaus, Albert, Sagnelli, Evangelista, and Lamberti, Monica

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, HBsAg, Logistic Model, Booster dose, medicine.disease_cause, Hepatitis B Antibodie, Healthcare students, Medical microbiology, Retrospective Studie, medicine, Humans, Hepatitis B Vaccines, Hepatitis B Antibodies, Child, HBV infection, HBV vaccination, Retrospective Studies, Hepatitis B virus, Vaccines, Synthetic, business.industry, Immunogenicity, Infant, Newborn, Biomarker, Hepatitis B Vaccine, Hepatitis B, medicine.disease, Anti-HBs titer, Vaccination, Titer, Infectious Diseases, Logistic Models, Italy, Immunology, Healthcare student, Female, business, Biomarkers, Human, Research Article
Abstract

Background Universal hepatitis B virus (HBV) vaccination of newborn babies was introduced in Italy in 1991 and was extended to 12-years-old children for the first 12 years of application so as to cover in a dozen years the Italian population aged 0-24 years. The aim of this study was to identify factors associated with long-term immunogenicity against HBV 17 years after primary vaccination in students attending medical schools in Naples, Italy. Methods 1,704 students attending the school of medicine, schools of the healthcare professions, or postgraduate medical schools of the Second University of Naples, Italy, from September 2012 to December 2013 were enrolled in this study. Of these, 588 had been vaccinated against HBV in infancy and 1,116 when 12 years old. Multivariate logistic regression analysis was used to identify factors associated with the level of long-term immunogenicity. Results All vaccinated subjects were HBsAg/anti-HBc negative: 270 (15.8%) had an anti-HBs titer between 1 and 9 IU/L, 987 (57.9%) between 10 and 400 IU/L, and 447 (26.3%) over 400 IU/L. When compared with the latter two subgroups, those with anti-HBs titers lower than 10 IU/L were younger (24 ± 5.2 years vs. 26 ± 4.9 years, p

Published
2015

7. Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

Author

Nicola Coppola, Caterina Sagnelli, Evangelista Sagnelli, Mariantonietta Pisaturo, Italo F. Angelillo, G. Tonziello, Coppola, N., Pisaturo, M., Tonziello, G., Sagnelli, C., Sagnelli, E., Angelillo, I. F., Coppola, Nicola, Pisaturo, M, Tonziello, G, Sagnelli, Caterina, Sagnelli, E, and Angelillo, Italo Francesco

Subjects
Male, medicine.medical_specialty, Alpha interferon, Interferon alpha-2, Polyethylene Glycol, Virus, Polyethylene Glycols, lcsh:Infectious and parasitic diseases, chemistry.chemical_compound, Medical microbiology, Chronic hepatitis, Pegylated interferon, Genotype, medicine, Humans, Meta-analysi, lcsh:RC109-216, Response to anti-HCV therapy, business.industry, Ribavirin, Interferon-alpha, Antiviral therapy in HCV patient, Hepatitis C, Chronic, Recombinant Protein, Virology, Recombinant Proteins, Tolerability of anti-HCV therapy, Meta-analysis, Infectious Diseases, Treatment Outcome, chemistry, Antiviral therapy in HCV patients, Female, business, Research Article, medicine.drug, Human
Abstract

Background Two formulations of Pegylated interferon (Peg-IFN) are on the market for treatment of chronic hepatitis C virus (HCV) infection. The purpose of this meta-analysis was to assess the efficacy of Peg-IFN α-2a versus Peg-IFN α-2b in combination with ribavirin in anti-human immunodeficiency virus (HIV)-negative patients with genotype 1 chronic HCV infection. Methods The following criteria were to be met for inclusion in the meta-analysis: (a) original data from randomized and non-randomized clinical trials; (b) study on the efficacy of conventional doses of Peg-IFN α-2a (180 μg/week) versus Peg-IFN α-2b (1.5 μg/kg of body weight/week), both in combination with ribavirin, in antiviral therapy-naïve HCV-genotype 1 subjects; (c) at least one of these primary outcomes: Rapid Virological Response (RVR); Early Complete Virological Response (EVR); End of Treatment Response (ETR); Sustained Virological Response (SVR); (d) odds ratio estimates of relative risk (RR) and associated 95% confidence intervals (CIs) or at least data enabling them to be computed; (e) English language; and (f) published as a full paper up to December 2011. Results Seven published studies met the inclusion criteria, allowing a meta-analysis on 3,026 patients. Peg-IFN α-2a and Peg-IFN α-2b showed similar rate of RVR (RR = 1.05; 95% CI = 0.87-1.27, p = 0.62) and SVR (RR = 1.08; 95% CI = 0.99-1.18, p = 0.098). Peg-IFN α-2a more frequently than Peg-IFN α-2b achieved EVR (RR = 1.11; 95% CI = 1.02-1.21, p = 0.013) and ETR (RR = 1.22; 95% CI = 1.14-1.31, p Conclusion The standard schedules of Peg-IFN α-2a and Peg-IFN α-2b, both in combination with ribavirin, can be used indifferently for patients with chronic HCV genotype 1 who are anti- to eliminate HIV-negative and antiviral treatment-naïve.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results